menu
    • menu
    [{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Chiauranib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chiauranib","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Chiauranib

    Menu

    Chiauranib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chiauranib,Monoclonal Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase III Chiauranib Trial Approved for Extensive Disease Small Cell Lung Cancer

                            Details : CS-2164 (chiauranib) is a novel molecular entity and a selective inhibitor of Aurora B, a key mitotic regulator, being developed for the first-line treatment of extensive stage small cell lung cancer.

                            Brand Name : CS-2164

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 01, 2024

                            Lead Product(s) : Chiauranib,Monoclonal Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chiauranib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chipscreen Received a Phase 1b/2 Clinical Trial of Chiauranib/CS2164 IND Clearance from the US Food and Drug A...

                            Details : Chiauranib is an innovative, 3-pathway targeted kinase small molecule inhibitor with high selectivity against Auroa B /VEGFRs/CSF1R currently entering Phase III clinical trials in China.

                            Brand Name : CS2164

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2021

                            Lead Product(s) : Chiauranib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth